Esperion to Report First Quarter 2020 Financial Results May 6, 2020
April 30 2020 - 8:00AM
Esperion (NASDAQ: ESPR) today announced it will report first
quarter 2020 financial results after the close of the U.S.
financial markets on May 6, 2020. Following the release, company
management will host a webcast and conference call at 4:30 p.m. ET
to discuss financial results and business progress.
Esperion Therapeutics
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the experienced Lipid
Management Team at Esperion is committed to developing new LDL-C
lowering medicines that will make a substantial impact on reducing
global cardiovascular disease, the leading cause of death around
the world. For more information, please visit
www.esperion.com and follow us on Twitter at
www.twitter.com/EsperionInc.
Esperion Therapeutics’ Commitment to Patients with
Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack and stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. living with elevated
levels of LDL-C despite taking maximally tolerated lipid-modifying
therapy — including individuals considered statin averse — leaving
them at high risk for cardiovascular events1. In the United States,
more than 50 percent of atherosclerotic cardiovascular disease
(ASCVD) patients and heterozygous familial hypercholesterolemia
(HeFH) patients who are not able to reach their guideline
recommended LDL-C levels with statins alone need less than a 40
percent reduction to reach their LDL-C threshold goal2.
Esperion's mission as the Lipid Management Company is to deliver
oral, once-daily medicines that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the clinical
development and commercialization plans for bempedoic acid tablet
and the bempedoic acid / ezetimibe fixed dose combination tablet,
including Esperion's timing, designs, plans for announcement of
results regarding its CLEAR Outcomes study and other ongoing
clinical studies for bempedoic acid tablet and the bempedoic acid /
ezetimibe combination fixed dose tablet, timing for the review and
approval of expanded indications for their effect on cardiovascular
events, and Esperion's expectations for the market for medicines to
lower LDL-C, including the commercial launch and market adoption of
bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose
combination tablet in the European Union. Any express or implied
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause Esperion's actual results to differ significantly from
those projected, including, without limitation, delays or failures
in Esperion’s clinical development and commercialization plans, or
approval of expanded indications, that existing cash resources may
be used more quickly than anticipated, that Otsuka is able to
successfully commercialize bempedoic acid and the bempedoic acid /
ezetimibe fixed dose combination tablet, the impact of COVID-19 on
our business, clinical activities and commercial development plans,
and the risks detailed in Esperion's filings with the Securities
and Exchange Commission. Any forward-looking statements contained
in this press release speak only as of the date hereof, and
Esperion disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
References(1) Esperion market research on file:
research project interviewing 350 physicians. Esperion
Therapeutics, Inc. Sept-Oct 2018.(2) Data on file: analysis of
NHANES database. Esperion Therapeutics, Inc. 2018.
Investor Contact:Alex
SchwartzEsperion734-249-3386aschwartz@esperion.com
Media Contact:Ben
ChurchEsperion734-864-6774bchurch@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024